Tutivia™ study confirms predictive value in transplant care

Verici Dx Plc

Verici Dx completed a pivotal clinical validation study for Tutivia™, a test designed to support early risk assessment in kidney transplant recipients. Conducted across thirteen centres in the United States, Europe and Australia, the prospective, blinded study evaluated the performance of Tutivia™ in predicting acute rejection (AR) within the first six months after transplant.

The study assessed 151 patients using a proprietary RNA sequencing platform that analyses gene expression associated with kidney injury, immune response, and graft protection. Tutivia™ applies an AI-driven algorithm to generate a patient-specific risk score between 0 and 100. A score above 50 is interpreted as high risk for acute rejection, providing clinicians with an actionable metric to tailor post-transplant care.

Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Search